Welcome to BioSeeker Group!

Triple Analysis: Lung Cancer, Lymphoma and Prostate Cancer

Additional Information

Published Date Sep 12, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3770
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lung Cancer, Lymphoma and Prostate Cancer in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Prostate Cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Lymphoma and Prostate Cancer.

    To find out more about Triple Analysis: Lung Cancer, Lymphoma and Prostate Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Lymphoma and Prostate Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part II: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part II: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part III: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

This Report Includes the Following Companies:
4SC
A&G Pharmaceutical
Abbott
Abiogen
Active Biotech
Adherex
Advanomics
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Agennix
Agenus
Aida Pharmaceuticals
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alfa Wassermann
Alfacell
Allos Therapeutics
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
American Gene Technology International
Amgen
Anavex Life Sciences
AndroBioSys
AngioChem
Antisense Pharma
Antisense Therapeutics
Antisoma
Anza Therapeutics
Aphios
ApopLogic Pharmaceuticals
Apotex
Aprea
Apricus Biosciences
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Axelar
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Benitec
Betapharma
Biocon
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biokine Therapeutics
Biolex
BioLineRx
BioMarin
BioNetWorks
BioNumerik
BioSante
Biostar
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Camurus
CanBas
Cancer Research Technology
Cel-Sci
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Chemokine Therapeutics
Chong Kun Dang
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
CLL Pharma
Colby
Cornerstone Pharmaceuticals
Coronado Biosciences
Cosmo Bioscience
Critical Outcome Technologies
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Dendreon
Dong-A
Dongkook Pharm
Dr Reddy’s
Dynavax Technologies
ECI
Eisai
Elara Pharmaceuticals
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Endocyte
Ensemble Discovery
EntreMed
Enzon
EpiCept
Epizyme
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Favrille
Ferring
Forma Therapeutics
Formula Pharmaceuticals
Fresenius
Galapagos
Galena Biopharma
Gemin X Biotechnologies
Gemin X Pharmaceuticals
Genencor
Genentech
Generex
Genmab
GENova Biotherapeutics
Genovax
GenPat77
Genta
GenVec
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlobeImmune
GlycoGenesys
Got-a-Gene
GP Pharm
Gradalis
Green Cross
GTx
Hanmi
Harbor BioSciences
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IGF Oncology
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Incyte Corporation
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intezyne Technologies
Intracel
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Italfarmaco
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
Karo Bio
Kiadis
Kinex
Kissei
Kyowa Hakko Kirin
Leo
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Medivation
Menarini
Merck & Co
Merck KGaA
Merrimack
Merrion Pharmaceuticals
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
Mojave Therapeutics
Molecular Insight
MolMed
Mologen
Mycenax
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
Novartis
Novogen
Noxxon
Nycomed Pharma
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Onconova
Oncothyreon
Oncovir
Orchestra Therapeutics
Orion Pharma
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Pantarhei Bioscience
PBL Therapeutics
Pepscan Therapeutics
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Pro-Pharmaceuticals
Progen
Progen Pharmaceuticals
Progenics Pharmaceuticals
ProNAi Therapeutics
ProStrakan
Q Chip
QLT
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Salzburg Therapeutics
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sapphire Therapeutics
Sareum
SBIO
Seattle Genetics
SeleXel
Selvita
Semafore Pharmaceuticals
Serometrix
SGX Pharmaceuticals
ShimodaAtlantic Oncology
Shire
Siena Biotech
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
Soligenix
Sophiris Bio
SRI International
SuperGen
SuppreMol
Supratek Pharma
Switch Pharma
Symphogen
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Tau Therapeutics
Taxolog
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
Tokai Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
Twinstrand Therapeutics
UCB
Unigene
United Biomedical
Vaccinex
Valeant
Vaxon Biotech
VaxOnco
Velacor Therapeutics
VentiRx Pharmaceuticals
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viralytics
ViroTarg
VM Discovery
Wyeth
XBiotech
Xencor
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zenotech
Zenyaku Kogyo
Zhejiang Beta Pharma
Zivena
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abarelix
abiraterone acetate
adecatumumab
aderbasib
AEZS-108
afatinib
aflibercept
alemtuzumab
ALT-801
alvocidib
amonafide dihydrochloride
amonafide malate
amrubicin hydrochloride
APC-100
APR-246
ARC-100
ARQ-197
astuprotimut-r
atrasentan
AVX-701
bafetinib
belagenpumatucel-L
belinostat
belotecan hydrochloride
bevacizumab
bexarotene
BIBF-1120
bicalutamide
BMS-777607
BMS-936558
bortezomib
BP-GMAX-CD1
brentuximab vedotin
buserelin
Cabozantinib
canfosfamide hydrochloride
carlumab
cediranib
celecoxib
cetuximab
cixutumumab
cladribine
crizotinib
custirsen
dacomitinib
danusertib
dasatinib
DCVax-prostate
degarelix
denileukin diftitox
denosumab
deslorelin
DI-17E6
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
elliptinium acetate
emepepimut-S
endostatin
entinostat
enzastaurin hydrochloride
epirubicin
erlotinib
estramustine phosphate sodium
ethinyl estradiol sulfonate
etoposide (1)
etoposide phosphate
everolimus
figitumumab
flutamide
fulvestrant
galiximab
gataparsen
GDC-0980
gefitinib
goserelin
GTx-758
GVAX
GVX-3322
GX-301
HBP-347
HE-3235
histrelin
ibritumomab tiuxetan
icotinib hydrochloride
idronoxil
imatinib mesilate
inecalcitol
iniparib
inotuzumab ozogamicin
INSM-18
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon (gamma1b)
interferon alfa-2b
interferon alpha-2b
interleukins
intetumumab
ipilimumab
irinotecan hydrochloride
irosustat
ispinesib mesylate
KX2-391
lapatinib ditosylate
lestaurtinib
leucine-doxorubicin
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
LY-2275796
MCS-110
MDV-3100
mitoxantrone
MLN-8237
motesanib diphosphate
Nab-docetaxel
nadroparin
necitumumab
nilutamide
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
OGX-427
olaparib
olaratumab
orteronel
ozarelix
paclitaxel
paclitaxel polyglumex
panitumumab
panobinostat
pazopanib hydrochloride
pemetrexed disodium
perifosine
pertuzumab
pixantrone
plitidepsin
PLX-3397
pralatrexate
ProstAtak
PROSTVAC
PRX-302
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
ramucirumab
razoxane
Reditux
retaspimycin
rhIFN-alpha
ridaforolimus
rilotumumab
rituximab
romidepsin
ruxolitinib
sagopilone
sargramostim
SB-939
siltuximab
sipuleucel-T
sobuzoxane
sorafenib tosylate
TAK-448
talactoferrin alfa
tandutinib
tasquinimod
tegafur + uracil
temsirolimus
Tenarad
teniposide
thymalfasin
TOK-001
topotecan
toremifene citrate
TRC-105
tremelimumab
trilostane
triptorelin
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
YM-155
zanolimumab
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Lymphoma and Prostate Cancer.
    To find out more about Triple Analysis: Lung Cancer, Lymphoma and Prostate Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Lymphoma and Prostate Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lymphoma, Pancreatic Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More


Triple Analysis: Leukemia, Cancer Vaccines and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Leukemia and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Leukemia and Pancreatic Cancer. Learn More


Triple Analysis: Leukemia, Lung Cancer and Lymphoma
This triple analysis focuses on cancer drug development strategies in Leukemia, Lung Cancer and Lymphoma. Learn More